Can anyone share how they have tackled their LASA policy/lists when it comes to addressing biosimilars and monoclonal antibodies. We think the nomenclature is easily confused and are evaluating possible safety impacts/look-alike, sound-alike risks as more of these products come to market. We would prefer to avoid blanket statements such as adding all monoclonal antibodies are at risk for LASA errors.
Thanks!